Hepalink

Hepalink, founded in 1998, is a global pharmaceutical enterprise specializing in the development, manufacturing, and commercialization of complex biopharmaceutical products. The company operates through four primary business segments: finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO) services, and diversified investment activities. Hepalink maintains a robust portfolio centered on heparin sodium and enoxaparin sodium, serving markets across Mainland China, Hong Kong, the United States, and Europe.

With a workforce of 1,000-5,000 employees, the organization integrates advanced quality management and program management services into its operational framework. The company’s technical capabilities extend to the production of recombinant pharmaceutical products, non-viral vectors, and gene therapy intermediates. Meet Hepalink's team to understand the leadership driving these specialized biopharmaceutical initiatives. The firm’s infrastructure supports comprehensive R&D, from initial development to large-scale manufacturing, ensuring compliance with international regulatory standards across its global supply chain.

Hepalink, listed under ticker SSE: 2399, continues to expand its footprint in the biopharmaceutical sector through strategic investments and technology consulting. The company’s revenue reached $774.7M, reflecting its significant market presence in the heparin and enoxaparin segments. Beyond core manufacturing, the firm engages in venture investment and biopharmaceutical technology development, positioning itself as a multifaceted player in the global healthcare industry. By leveraging its expertise in naturally derived pharmaceutical products and advanced manufacturing, Hepalink maintains a competitive edge in the highly regulated pharmaceutical landscape.